CN108822120A - Fl118氨基酸盐酸盐及其制备方法与应用 - Google Patents
Fl118氨基酸盐酸盐及其制备方法与应用 Download PDFInfo
- Publication number
- CN108822120A CN108822120A CN201810758019.0A CN201810758019A CN108822120A CN 108822120 A CN108822120 A CN 108822120A CN 201810758019 A CN201810758019 A CN 201810758019A CN 108822120 A CN108822120 A CN 108822120A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- preparation
- formula
- reaction
- acid hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- -1 amino acid hydrochloride Chemical class 0.000 title abstract description 39
- 238000006243 chemical reaction Methods 0.000 claims abstract description 96
- 150000001413 amino acids Chemical class 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 19
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 8
- 102000003915 DNA Topoisomerases Human genes 0.000 claims abstract description 4
- 108090000323 DNA Topoisomerases Proteins 0.000 claims abstract description 4
- 201000010099 disease Diseases 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 111
- RPFYDENHBPRCTN-NRFANRHFSA-N mdo-cpt Chemical compound C1=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=CC2=C1OCO2 RPFYDENHBPRCTN-NRFANRHFSA-N 0.000 claims description 60
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 48
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 48
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 32
- 235000001014 amino acid Nutrition 0.000 claims description 29
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 15
- 238000012805 post-processing Methods 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical class CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- 239000012295 chemical reaction liquid Substances 0.000 claims description 2
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 claims description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 5
- 239000003446 ligand Substances 0.000 abstract description 3
- 239000002699 waste material Substances 0.000 abstract description 2
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 71
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 40
- 238000003756 stirring Methods 0.000 description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 28
- 229940024606 amino acid Drugs 0.000 description 22
- 239000003480 eluent Substances 0.000 description 22
- 239000000706 filtrate Substances 0.000 description 22
- 239000012141 concentrate Substances 0.000 description 21
- 239000000047 product Substances 0.000 description 17
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 239000007789 gas Substances 0.000 description 13
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 13
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 13
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 13
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 11
- 230000006837 decompression Effects 0.000 description 11
- 238000010898 silica gel chromatography Methods 0.000 description 11
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 238000001035 drying Methods 0.000 description 10
- 238000012544 monitoring process Methods 0.000 description 10
- 239000003960 organic solvent Substances 0.000 description 10
- 238000001953 recrystallisation Methods 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 238000001291 vacuum drying Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- ZAIZDXVMSSDZFA-QRPNPIFTSA-N (2s)-2-amino-3-phenylpropanoic acid;hydrochloride Chemical class Cl.OC(=O)[C@@H](N)CC1=CC=CC=C1 ZAIZDXVMSSDZFA-QRPNPIFTSA-N 0.000 description 1
- OSUIUMQSEFFIKM-WCCKRBBISA-N (2s)-2-amino-4-methylsulfanylbutanoic acid;hydrochloride Chemical class Cl.CSCC[C@H](N)C(O)=O OSUIUMQSEFFIKM-WCCKRBBISA-N 0.000 description 1
- RPAJSBKBKSSMLJ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;hydrochloride Chemical class Cl.OC(=O)[C@@H](N)CCC(O)=O RPAJSBKBKSSMLJ-DFWYDOINSA-N 0.000 description 1
- ILYVXUGGBVATGA-DKWTVANSSA-N (2s)-2-aminopropanoic acid;hydrochloride Chemical class Cl.C[C@H](N)C(O)=O ILYVXUGGBVATGA-DKWTVANSSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical class Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 101710150820 Cellular tumor antigen p53 Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960003707 glutamic acid hydrochloride Drugs 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
一种式(I)所示的FL118氨基酸盐酸盐,由氨基酸配体基团与FL118进行偶联得到的新衍生物,再经进一步反应形成盐酸盐而得,本发明FL118氨基酸盐酸盐的制备方法反应条件温和、经济高效、收率好且产品质量佳,同时反应三废污染少,适合工业化生产;本发明FL118氨基酸盐酸盐具有更良好的水溶性,更高的活性,稳定性和生物利用度等,有利于确定药物的给药方式,减少给药次数,可制备用于治疗哺乳动物受试者体内与拓扑异构酶I相关的疾病的药物,并且可制备用于针对哺乳动物受试者体内实体肿瘤的药物;
Description
(一)技术领域
本发明涉及一系列抗肿瘤化合物FL118的氨基酸盐酸盐及其制备方法与应用。
(二)背景技术
罗斯威尔·帕克癌症研究所(RPCI)的科学家在2012年发现FL118(10,11-亚甲二氧基-20(S)-喜树碱)能抑制几个与癌细胞生存和繁殖能力密切相关的基因。其分子结构类似于喜树碱,研究报道了FL118制剂内酯环中羟基基团的构效关系,他们分析了FL118其它几种由FL118衍生的化合物,FL118不管是在体内还是在体外都可以高效地抑制癌症生存蛋白,且FL118的存在促使癌症细胞死亡独立于肿瘤抑制基因p53,对肿瘤细胞的体内外抑制活性均极好,可能会成为早期和晚期癌、转移性或非转移性癌症的有效控制药物。
氨基酸是生命活动中最基本的物质,是生命代谢的物质基础,肿瘤细胞对氨基酸的需求远大于正常组织。氨基酸具有多个活性官能团,可以用来固定具有生物活性的分子,如蛋白质、糖类、多肽等,其支链可以与小肽、药物或交联剂等连接,促进细胞的黏附和生长。实验表明将氨基酸引入抗肿瘤药物分子中,可以提高其对肿瘤细胞的选择性,缓解药物对细胞的毒性等。基于FL118水溶性前药的设计需求,氨基酸盐酸盐作为水溶性配基是体内内源性物质,无毒副作用,已经广泛应用于其他药物的水溶性前药设计,结合抗肿瘤化合物FL118的结构特点和构效关系,用氨基酸对FL118的20位进行结构修饰形成水溶性前药得到更有利于癌症患者的高效、低毒的抗肿瘤前药。
(三)发明内容
在深入研究FL118及其衍生物后,发明人发现用氨基酸配体基团与FL118进行偶联得到的新衍生物,再经进一步反应形成盐酸盐形式,所得到的FL118氨基酸盐酸盐具有更良好的水溶性,更高的活性,稳定性和生物利用度等,有利于确定药物的给药方式,减少给药次数,有望开发成新一代抗肿瘤药物。
本发明的技术方案如下:
一种式(I)所示的FL118氨基酸盐酸盐:
式(I)中,R选自如下之一天然氨基酸取代基:甘氨酸、丙氨酸、缬氨酸、亮氨酸、异亮氨酸、甲硫氨酸、谷氨酸、苯丙氨酸、脯氨酸或赖氨酸取代基;结构式为(波浪线处表示与FL118的连接位点):
本发明还提供了所述式(I)所示的FL118氨基酸盐酸盐的制备方法,所述制备方法为:
(1)将式(II)所示FL118、BOC(叔丁氧羰基)保护的氨基酸、1-乙基-(3-二甲基氨基丙基)碳二亚胺盐酸盐(EDCI)、4-二甲氨基吡啶(DMAP)与反应溶剂混合,在15~50℃下搅拌反应,TLC监测至反应结束,反应液经后处理,得到偶联产物;
(2)将步骤(1)所得偶联产物溶于甲醇中,通入HCl气体,TLC监测至反应结束,反应液经后处理,得到式(I)所示的FL118氨基酸盐酸盐。
本发明所述步骤(1)中,
所述反应溶剂为氯仿或二氯甲烷,优选氯仿;
所述反应溶剂的体积用量以FL118的物质的量计为1~10mL/mmol,优选3~5mL/mmol;
所述FL118与BOC保护的氨基酸的物质的量之比为1:1~10,优选1:3;
所述FL118与1-乙基-(3-二甲基氨基丙基)碳二亚胺盐酸盐的物质的量之比为1:1~5,优选1:3;
所述4-二甲氨基吡啶的质量用量以FL118的物质的量计为1~20mg/mmol,优选5~10mg/mmol;
更为具体的,推荐步骤(1)按如下方法进行:
室温下,先将BOC保护的氨基酸溶于氯仿中,溶解完全后加入1-乙基-(3-二甲基氨基丙基)碳二亚胺盐酸盐,搅拌30min,再加入4-二甲氨基吡啶,继续搅拌30min,最后加入FL118,于25℃下搅拌反应3h,之后反应液经后处理,得到偶联产物;
所述反应液后处理的方法为:反应结束后,向反应液中加入反应液体积1~5倍(优选3倍)的氯仿或二氯甲烷(优选氯仿),抽滤,滤液依次用饱和氯化钠水溶液、饱和碳酸氢钠水溶液洗涤,再用无水硫酸镁干燥,抽滤,滤液减压浓缩至干,所得浓缩物进行硅胶柱层析,洗脱剂为二氯甲烷与甲醇体积比100:1的混合液,收集含目标化合物的洗脱液,蒸除溶剂并干燥,得到深黄色偶联产物。
本发明所述步骤(2)中,
所述甲醇的体积用量以偶联产物的质量计为30~100mL/g,优选50mL/g;
所述HCl气体由浓硫酸(98wt%)与氯化钠反应所得,并可通过控制浓硫酸滴入氯化钠的速度来调节氯化氢气体的流速;
所述反应液后处理的方法为:反应结束后,反应液减压蒸干,剩余物质用无水甲醇和乙醚重结晶,得到式(I)所示的FL118氨基酸盐酸盐。
所述FL118的结构式如式(II)所示:
所述BOC保护的氨基酸的结构式为如下之一所示:
所述偶联产物的结构式如下之一所示:
本发明制得的FL118氨基酸盐酸盐及其与人体可接受的药用载体制成的药物组合物可应用于制备治疗哺乳动物受试者体内与拓扑异构酶I相关的疾病的药物,或者应用于制备针对哺乳动物受试者体内实体肿瘤的药物。
本发明的有益效果在于:本发明FL118氨基酸盐酸盐的制备方法反应条件温和、经济高效、收率好且产品质量佳,同时反应三废污染少,适合工业化生产。本发明FL118氨基酸盐酸盐可制备用于治疗哺乳动物受试者体内与拓扑异构酶I相关的疾病的药物。本发明FL118氨基酸盐酸盐可制备用于针对哺乳动物受试者体内实体肿瘤的药物。
(四)具体实施方式
下面通过具体实施例对本发明进行进一步描述,但本发明的保护范围并不仅限于此。
实施例1:FL118甘氨酸盐酸盐衍生物的制备(1)
在25mL圆底烧瓶中加入BOC保护甘氨酸(10mmol)和氯仿(20mL),25℃搅拌溶解,再加入EDCI(10mmol),25℃搅拌0.5h,接着加入DMAP(50mg),25℃搅拌0.5h,最后加入FL118(3mmol),25℃搅拌反应3h,得到淡黄色悬浊液,反应结束后,向反应液中加入氯仿(40mL),抽滤,滤液依次用饱和氯化钠水溶液和饱和碳酸氢钠水溶液洗涤,再用无水硫酸镁干燥,抽滤,滤液减压浓缩至干,所得浓缩物进行硅胶柱层析,洗脱剂为体积比100:1的二氯甲烷与甲醇混合液,收集含目标组分的洗脱液,浓缩干燥后将反应液产物溶于25ml有机溶剂甲醇中,在氯化氢气体的作用下,反应液颜色发生变化,TLC跟踪监测40分钟至反应不再进行,甲醇反应液后处理,反应液真空干燥后加入无水甲醇和乙醚重结晶。即得FL118甘氨酸盐酸盐衍生物,产率70%。
1H NMR(600MHz,DMSO-d6)δ:8.58(s,3H),8.47(s,1H),7.50(s,1H),7.43(s,1H),7.20(s,1H),6.29(d,J=1.6Hz,2H),5.53(s,2H),5.19(m,2H),3.66(m,2H),2.18(m,2H),0.96(t,J=7.4Hz,3H).
13C NMR(151MHz,DMSO-d6)δ:167.30,167.28,156.92,152.00,150.02,149.23,146.84,146.80,145.14,130.87,128.85,126.17,118.45,104.77,103.64,103.18,95.23,77.93,66.80,50.61,40.40,30.66,8.02.
实施例2:FL118丙氨酸盐酸盐衍生物的制备(2)
在25mL圆底烧瓶中加入BOC保护丙氨酸(10mmol)和氯仿(20mL),25℃搅拌溶解,再加入EDCI(10mmol),25℃搅拌0.5h,接着加入DMAP(50mg),25℃搅拌0.5h,最后加入FL118(3mmol),25℃搅拌反应3h,得到淡黄色悬浊液,反应结束后,向反应液中加入氯仿(40mL),抽滤,滤液依次用饱和氯化钠水溶液和饱和碳酸氢钠水溶液洗涤,再用无水硫酸镁干燥,抽滤,滤液减压浓缩至干,所得浓缩物进行硅胶柱层析,洗脱剂为体积比100:1的二氯甲烷与甲醇混合液,收集含目标组分的洗脱液,浓缩干燥后将反应液产物溶于25ml有机溶剂甲醇中,在氯化氢气体的作用下,反应液颜色发生变化,TLC跟踪监测40分钟至反应不再进行,甲醇反应液后处理,反应液真空干燥后加入无水甲醇和乙醚重结晶。即得FL118丙氨酸盐酸盐衍生物,产率75%。
1H NMR(600MHz,DMSO-d6)δ:8.92(s,2H),8.79(s,1H),8.48(d,J=3.5Hz,1H),7.52(d,J=4.0Hz,1H),7.44(d,J=6.4Hz,1H),7.17(d,J=12.1Hz,1H),6.29(d,J=4.2Hz,2H),5.53(m,2H),5.21(d,J=5.1Hz,2H),3.90(m,1H),2.25(m,2H),1.59(m,3H),0.96(td,J=7.4,5.5Hz,3H).
13C NMR(151MHz,DMSO-d6)δ:169.06,167.17,156.92,151.98,150.03,149.23,146.96,146.89,144.87,130.87,128.88,126.22,118.57,104.94,103.65,103.17,94.79,77.92,66.86,50.66,48.25,31.19,16.29,8.04.
实施例3:FL118缬氨酸盐酸盐衍生物的制备(3)
在25mL圆底烧瓶中加入BOC保护缬氨酸(10mmol)和氯仿(20mL),25℃搅拌溶解,再加入EDCI(10mmol),25℃搅拌0.5h,接着加入DMAP(50mg),25℃搅拌0.5h,最后加入FL118(3mmol),25℃搅拌反应3h,得到淡黄色悬浊液,反应结束后,向反应液中加入氯仿(40mL),抽滤,滤液依次用饱和氯化钠水溶液和饱和碳酸氢钠水溶液洗涤,再用无水硫酸镁干燥,抽滤,滤液减压浓缩至干,所得浓缩物进行硅胶柱层析,洗脱剂为体积比100:1的二氯甲烷与甲醇混合液,收集含目标组分的洗脱液,浓缩干燥后将反应液产物溶于25ml有机溶剂甲醇中,在氯化氢气体的作用下,反应液颜色发生变化,TLC跟踪监测40分钟至反应不再进行,甲醇反应液后处理,反应液真空干燥后加入无水甲醇和乙醚重结晶。即得FL118缬氨酸盐酸盐衍生物,产率72%。
1H NMR(600MHz,DMSO-d6)δ:8.96(s,3H),8.50(d,J=5.8Hz,1H),7.55(s,1H),7.43(s,1H),7.32(s,1H),6.30(s,2H),5.50(m,2H),5.26(m,2H),4.10(s,1H),2.22(m,2H),1.17(d,J=7.0Hz,1H),1.10(dd,J=14.9,7.0Hz,3H),1.05(d,J=7.0Hz,3H),0.95(t,J=7.3Hz,3H).
13C NMR(151MHz,DMSO-d6)δ:167.54,167.13,156.93,151.88,150.21,149.15,147.00,146.89,144.84,131.22,128.85,126.16,118.51,104.97,103.68,103.12,95.58,78.14,66.84,57.46,54.32,31.21,30.34,18.42,8.10.
实施例4:FL118亮氨酸盐酸盐衍生物的制备(4)
在25mL圆底烧瓶中加入BOC保护亮氨酸(10mmol)和氯仿(20mL),25℃搅拌溶解,再加入EDCI(10mmol),25℃搅拌0.5h,接着加入DMAP(50mg),25℃搅拌0.5h,最后加入FL118(3mmol),25℃搅拌反应3h,得到淡黄色悬浊液,反应结束后,向反应液中加入氯仿(40mL),抽滤,滤液依次用饱和氯化钠水溶液和饱和碳酸氢钠水溶液洗涤,再用无水硫酸镁干燥,抽滤,滤液减压浓缩至干,所得浓缩物进行硅胶柱层析,洗脱剂为体积比100:1的二氯甲烷与甲醇混合液,收集含目标组分的洗脱液,浓缩干燥后将反应液产物溶于25ml有机溶剂甲醇中,在氯化氢气体的作用下,反应液颜色发生变化,TLC跟踪监测40分钟至反应不再进行,甲醇反应液后处理,反应液真空干燥后加入无水甲醇和乙醚重结晶。即得FL118亮氨酸盐酸盐衍生物,产率76%。
1H NMR(600MHz,DMSO-d6)δ:8.82(s,1H),8.65(d,J=5.4Hz,2H),8.49(s,1H),7.53(d,J=1.3Hz,1H),7.43(s,1H),7.21(d,J=7.1Hz,1H),6.30(s,2H),5.52(d,J=5.1Hz,2H),5.25(m,2H),4.41(m,1H),2.19(m,2H),1.83(m,1H),1.74(m,1H),1.21(m,1H),0.99(m,9H).
13C NMR(151MHz,DMSO-d6)δ:169.68,167.22,156.93,151.96,150.13,149.20,146.91,146.91,145.41,130.75,128.79,126.11,118.16,104.83,103.62,103.17,95.23,78.03,66.80,50.58,50.55,40.65,30.70,24.29,22.64,22.58,8.13.
实施例5:FL118异亮氨酸盐酸盐衍生物的制备(5)
在25mL圆底烧瓶中加入BOC保护异亮氨酸(10mmol)和氯仿(20mL),25℃搅拌溶解,再加入EDCI(10mmol),25℃搅拌0.5h,接着加入DMAP(50mg),25℃搅拌0.5h,最后加入FL118(3mmol),25℃搅拌反应3h,得到淡黄色悬浊液,反应结束后,向反应液中加入氯仿(40mL),抽滤,滤液依次用饱和氯化钠水溶液和饱和碳酸氢钠水溶液洗涤,再用无水硫酸镁干燥,抽滤,滤液减压浓缩至干,所得浓缩物进行硅胶柱层析,洗脱剂为体积比100:1的二氯甲烷与甲醇混合液,收集含目标组分的洗脱液,浓缩干燥后将反应液产物溶于25ml有机溶剂甲醇中,在氯化氢气体的作用下,反应液颜色发生变化,TLC跟踪监测40分钟至反应不再进行,甲醇反应液后处理,反应液真空干燥后加入无水甲醇和乙醚重结晶。即得FL118异亮氨酸盐酸盐衍生物,产率70%。
1H NMR(600MHz,DMSO-d6)δ:8.67(s,3H),8.42(m,1H),7.39(m,2H),7.19(m,1H),6.23(s,2H),5.48(d,J=5.2Hz,2H),5.12(d,J=6.8Hz,2H),4.35(m,1H),2.18(m,2H),1.33(m,1H),1.04(m,2H),0.93(m,9H).
13C NMR(151MHz,DMSO-d6)δ:167.83,167.22,157.07,152.01,149.67,149.24,146.81,146.78,144.72,130.91,128.58,126.17,118.62,104.64,103.56,103.18,95.29,78.22,66.97,56.91,50.64,36.71,30.82,24.90,14.72,12.02,7.92.
实施例6:FL118甲硫氨酸盐酸盐衍生物的制备(6)
在25mL圆底烧瓶中加入BOC保护甲硫氨酸(10mmol)和氯仿(20mL),25℃搅拌溶解,再加入EDCI(10mmol),25℃搅拌0.5h,接着加入DMAP(50mg),25℃搅拌0.5h,最后加入FL118(3mmol),25℃搅拌反应3h,得到淡黄色悬浊液,反应结束后,向反应液中加入氯仿(40mL),抽滤,滤液依次用饱和氯化钠水溶液和饱和碳酸氢钠水溶液洗涤,再用无水硫酸镁干燥,抽滤,滤液减压浓缩至干,所得浓缩物进行硅胶柱层析,洗脱剂为体积比100:1的二氯甲烷与甲醇混合液,收集含目标组分的洗脱液,浓缩干燥后将反应液产物溶于25ml有机溶剂甲醇中,在氯化氢气体的作用下,反应液颜色发生变化,TLC跟踪监测40分钟至反应不再进行,甲醇反应液后处理,反应液真空干燥后加入无水甲醇和乙醚重结晶。即得FL118甲硫氨酸盐酸盐衍生物,产率71%。
1H NMR(600MHz,DMSO-d6)δ:8.96(m,2H),8.75(d,J=5.7Hz,1H),8.47(s,1H),7.50(m,1H),7.42(m,1H),7.23(m,1H),6.29(dd,J=6.7Hz,J=2.0Hz,2H),5.53(m,2H),5.21(m,2H),3.68(m,1H),3.00(m,2H),2.21(m,3H),2.07(m,2H),0.97(m,3H).
13C NMR(151MHz,DMSO-d6)δ:168.17,167.22,156.93,151.97,150.10,149.23,147.00,146.95,145.27,130.78,128.89,126.20,118.46,104.88,103.66,103.15,95.08,78.37,66.90,51.43,50.68,30.32,28.71,14.75,8.07.
实施例7:FL118谷氨酸盐酸盐衍生物的制备(7)
在25mL圆底烧瓶中加入BOC保护谷氨酸(10mmol)和氯仿(20mL),25℃搅拌溶解,再加入EDCI(10mmol),25℃搅拌0.5h,接着加入DMAP(50mg),25℃搅拌0.5h,最后加入FL118(3mmol),25℃搅拌反应3h,得到淡黄色悬浊液,反应结束后,向反应液中加入氯仿(40mL),抽滤,滤液依次用饱和氯化钠水溶液和饱和碳酸氢钠水溶液洗涤,再用无水硫酸镁干燥,抽滤,滤液减压浓缩至干,所得浓缩物进行硅胶柱层析,洗脱剂为体积比100:1的二氯甲烷与甲醇混合液,收集含目标组分的洗脱液,浓缩干燥后将反应液产物溶于25ml有机溶剂甲醇中,在氯化氢气体的作用下,反应液颜色发生变化,TLC跟踪监测40分钟至反应不再进行,甲醇反应液后处理,反应液真空干燥后加入无水甲醇和乙醚重结晶。即得FL118谷氨酸盐酸盐衍生物,产率76%。
1H NMR(600MHz,DMSO-d6)δ:8.84(s,3H),8.45(s,1H),7.47(m,2H),7.14(s,1H),6.29(s,2H),5.53(s,2H),5.17(d,J=11.6Hz,2H),4.56(s,1H),3.63(s,2H),2.76(m,1H),2.20(m,3H),0.95(m,3H).
13C NMR(151MHz,DMSO-d6)δ:172.73,169.02,167.41,156.93,151.94,150.10,149.18,146.98,146.94,145.19,130.75,128.78,126.11,118.14,104.91,103.62,103.20,95.07,78.14,66.89,52.11,51.22,30.69,29.16,25.85,8.10.
实施例8:FL118苯丙氨酸盐酸盐衍生物的制备(8)
在25mL圆底烧瓶中加入BOC保护苯丙氨酸(10mmol)和氯仿(20mL),25℃搅拌溶解,再加入EDCI(10mmol),25℃搅拌0.5h,接着加入DMAP(50mg),25℃搅拌0.5h,最后加入FL118(3mmol),25℃搅拌反应3h,得到淡黄色悬浊液,反应结束后,向反应液中加入氯仿(40mL),抽滤,滤液依次用饱和氯化钠水溶液和饱和碳酸氢钠水溶液洗涤,再用无水硫酸镁干燥,抽滤,滤液减压浓缩至干,所得浓缩物进行硅胶柱层析,洗脱剂为体积比100:1的二氯甲烷与甲醇混合液,收集含目标组分的洗脱液,浓缩干燥后将反应液产物溶于25ml有机溶剂甲醇中,在氯化氢气体的作用下,反应液颜色发生变化,TLC跟踪监测40分钟至反应不再进行,甲醇反应液后处理,反应液真空干燥后加入无水甲醇和乙醚重结晶。即得FL118苯丙氨酸盐酸盐衍生物,产率77%。
1H NMR(600MHz,DMSO-d6)δ:8.92(m,2H),8.76(m,1H),8.50(m,2H),8.01(t,J=6.8Hz,1H),7.43(m,7H),6.30(d,J=2.2Hz,1H),5.51(m,2H),5.21(m,2H),4.61(s,1H),3.30(m,2H),2.04(m,2H),0.76(m,3H).
13C NMR(151MHz,DMSO-d6)δ:168.04,167.22,156.94,151.98,150.20,149.25,147.04,146.93,144.66,135.39,130.78,129.99,129.08,128.85,127.36,126.21,118.46,105.00,103.68,103.16,95.27,78.32,66.84,53.23,50.69,36.39,30.42,7.80.
实施例9:FL118脯氨酸盐酸盐衍生物的制备(9)
在25mL圆底烧瓶中加入BOC保护脯氨酸(10mmol)和氯仿(20mL),25℃搅拌溶解,再加入EDCI(10mmol),25℃搅拌0.5h,接着加入DMAP(50mg),25℃搅拌0.5h,最后加入FL118(3mmol),25℃搅拌反应3h,得到淡黄色悬浊液,反应结束后,向反应液中加入氯仿(40mL),抽滤,滤液依次用饱和氯化钠水溶液和饱和碳酸氢钠水溶液洗涤,再用无水硫酸镁干燥,抽滤,滤液减压浓缩至干,所得浓缩物进行硅胶柱层析,洗脱剂为体积比100:1的二氯甲烷与甲醇混合液,收集含目标组分的洗脱液,浓缩干燥后将反应液产物溶于25ml有机溶剂甲醇中,在氯化氢气体的作用下,反应液颜色发生变化,TLC跟踪监测40分钟至反应不再进行,甲醇反应液后处理,反应液真空干燥后加入无水甲醇和乙醚重结晶。即得FL118苯丙氨酸盐酸盐衍生物,产率77%。
1H NMR(600MHz,DMSO-d6)δ:10.10(d,J=6.4Hz,1H),9.00(d,J=6.2Hz,1H),8.49(s,1H),7.54(s,1H),7.45(s,1H),7.22(s,1H),6.30(s,2H),5.54(d,J=2.3Hz,2H),5.24(d,J=3.8Hz,2H),4.91(m,1H),3.22(d,J=8.4Hz,2H),2.41(m,1H),2.20(m,3H),2.02(m,1H),1.91(m,1H),0.97(t,J=7.4Hz,3H).
13C NMR(151MHz,DMSO-d6)δ:168.99,167.36,156.95,151.97,150.11,149.23,146.96,146.89,145.51,130.80,128.92,126.19,117.97,104.88,103.65,103.15,95.14,78.44,66.79,58.83,50.67,45.63,30.43,28.66,23.07,8.12.
实施例10:FL118赖氨酸盐酸盐衍生物的制备(10)
在25mL圆底烧瓶中加入(S)-2,6-二叔丁氧羰基氨基己酸(15mmol)和二氯甲烷(10mL),30℃搅拌溶解,再加入EDCI(15mmol),30℃搅拌0.5h,接着加入DMAP(50mg),30℃搅拌0.5h,最后加入FL118(5mmol),30℃搅拌反应3h,得到淡黄色悬浊液,反应结束后,向反应液中加入二氯甲烷(20mL),抽滤,滤液依次用饱和氯化钠水溶液和饱和碳酸氢钠水溶液洗涤,再用无水硫酸镁干燥,抽滤,滤液减压浓缩至干,所得浓缩物进行硅胶柱层析,洗脱剂为体积比100:1的二氯甲烷与甲醇混合液,收集含目标组分的洗脱液,浓缩干燥后将反应液产物溶于20ml有机溶剂甲醇中,在氯化氢气体的作用下,反应液颜色发生变化,TLC跟踪监测60分钟至反应不再进行,甲醇反应液后处理,反应液真空干燥后加入无水甲醇和乙醚重结晶。即得FL118赖氨酸盐酸盐衍生物,产率70%。
1H NMR(600MHz,DMSO-d6)δ:8.93(d,J=5.6Hz,1H),8.73(d,J=5.6Hz,2H),8.48(s,1H),8.10(s,2H),7.53(d,J=2.5Hz,1H),7.45(d,J=13.9Hz,1H),7.21(m,1H),6.30(s,2H),5.54(m,2H),5.23(m,2H),4.49(m,1H),2.79(m,2H),2.24(m,2H),2.00(m,2H),1.67(m,4H),0.96(t,J=7.4Hz,3H).
13C NMR(151MHz,DMSO-d6)δ:169.34,167.31,156.92,152.02,150.10,149.25,146.93,145.21,144.82,130.84,128.89,126.19,118.26,104.86,103.66,103.16,95.14,78.02,66.88,51.67,50.64,38.65,30.75,29.83,26.68,21.50,8.14.
实施例11:式(I)所示化合物对肿瘤细胞增殖抑制活性
(1)实验原理:MTT法是一种从数量上检测细胞相对存活率的方法。只有活细胞的线粒体中才存在琥珀酸脱氢酶,该酶具有将MTT还原为甲臜(Formazan)结晶的能力,而死细胞无此功能。该甲臜晶体呈蓝紫色且不溶于水,用二甲基亚矾或酸性异丙醇将其溶解后,在560nm处测定其光吸收值OD,吸光值的大小能够间接反映活细胞数量,并计算出细胞的存活率。在一定细胞数量范围内,MTT结晶形成的量与活细胞数量成正比,即可预测药物对细胞活性的影响。本实验通过MTT法检测药物细胞毒性试验来确定药物最大毒性剂量。
(2)实验材料:人肺癌细胞(A549)、人结肠癌细胞(HCT116)、人肝癌细胞(HepG-2),人子宫颈癌细胞(Hela)从中国科学院典型培养物保藏委员会细胞库购买。
(3)实验步骤及检测方法:
(a)配制PBS缓冲液(pH7.2-7.4):10ml 10×PBS缓冲液加无菌水至100ml,4℃保存备用。配制MTT溶液:称取250mgMTT,放入小烧杯中,加50mlPBS缓冲液在电磁力搅拌机上搅拌30min,用0.22um的微孔滤器除菌,分装,4℃保存备用。
(b)待实验细胞培养至80-90%左右融合时,用胰蛋白酶-EDTA(0.02%)将细胞消化下来,取20μL消化后的细胞悬液(2mL)加入到180μL DMEM培养基中,吹散,取吹打均匀后的细胞悬液10μL加入到血细胞计数板的计数室中,低倍镜下观察,计数。计算单个发亮圆球的数量,抱团细胞计作一个细胞,对于占线细胞,只数左边线和上边线上的。调节细胞密度为2×105cell/mL,将细胞接种于96孔板内,每孔200μL,放入培养箱中培养24h。
(c)将FL118及其衍生物初步溶解于DMSO中,配制成浓度为1mM的母液。给药前用含1%FBS的完全DMEM培养基稀释成0.008,0.04,0.20,1.00,5.00,10.00μM(HCT116细胞系、HepG-2细胞系)/0.032,0.16,0.8,4.00,10.00,20.00μM(A549细胞系、Hela细胞系)浓度梯度的药物溶液。
(d)待细胞达80%融合时,弃上清,实验孔每孔加入200μL不同药物溶液,每个样品浓度设置3个平行孔,空白孔每孔加入200μL含1%FBS的完全DMEM培养基作为空白对照。将加好药的96孔板放入37℃,5%CO2的培养箱中继续培养72h,之后每孔加入20μL 5mg/mL的MTT溶液(PBS溶解),继续培养4h。取出,小心弃上清,每孔加入150μL DMSO溶液溶解蓝紫色结晶产物。将96孔板放在微量振荡器上震荡溶解20分钟,用酶标仪设定参比波长为630nm,在570nm处检测吸光度OD值。取平均数,按下列公式算细胞存活率:
细胞存活率%=(OD实验组-OD空白组)/(OD对照组-OD空白组)×100
Claims (9)
1.一种式(I)所示的FL118氨基酸盐酸盐:
式(I)中,R选自如下之一天然氨基酸取代基:甘氨酸、丙氨酸、缬氨酸、亮氨酸、异亮氨酸、甲硫氨酸、谷氨酸、苯丙氨酸、脯氨酸或赖氨酸取代基;结构式为:
2.如权利要求1所述式(I)所示的FL118氨基酸盐酸盐的制备方法,其特征在于,所述制备方法为:
(1)将式(II)所示FL118、BOC保护的氨基酸、1-乙基-(3-二甲基氨基丙基)碳二亚胺盐酸盐、4-二甲氨基吡啶与反应溶剂混合,在15~50℃下搅拌反应,TLC监测至反应结束,反应液经后处理,得到偶联产物;
所述反应溶剂为氯仿或二氯甲烷;
(2)将步骤(1)所得偶联产物溶于甲醇中,通入HCl气体,TLC监测至反应结束,反应液经后处理,得到式(I)所示的FL118氨基酸盐酸盐;
所述FL118的结构式如式(II)所示:
所述BOC保护的氨基酸的结构式为如下之一所示:
所述偶联产物的结构式如下之一所示:
3.如权利要求2所述的制备方法,其特征在于,步骤(1)中,所述反应溶剂的体积用量以FL118的物质的量计为1~10mL/mmol。
4.如权利要求2所述的制备方法,其特征在于,步骤(1)中,所述FL118与BOC保护的氨基酸的物质的量之比为1:1~10。
5.如权利要求2所述的制备方法,其特征在于,步骤(1)中,所述FL118与1-乙基-(3-二甲基氨基丙基)碳二亚胺盐酸盐的物质的量之比为1:1~5。
6.如权利要求2所述的制备方法,其特征在于,步骤(1)中,所述4-二甲氨基吡啶的质量用量以FL118的物质的量计为1~20mg/mmol。
7.如权利要求2所述的制备方法,其特征在于,步骤(2)中,所述甲醇的体积用量以偶联产物的质量计为30~100mL/g。
8.如权利要求1所述式(I)所示的FL118氨基酸盐酸盐及其与人体可接受的药用载体制成的药物组合物在制备治疗哺乳动物受试者体内与拓扑异构酶I相关的疾病的药物中的应用。
9.如权利要求1所述式(I)所示的FL118氨基酸盐酸盐及其与人体可接受的药用载体制成的药物组合物在制备针对哺乳动物受试者体内实体肿瘤的药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810758019.0A CN108822120A (zh) | 2018-07-11 | 2018-07-11 | Fl118氨基酸盐酸盐及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810758019.0A CN108822120A (zh) | 2018-07-11 | 2018-07-11 | Fl118氨基酸盐酸盐及其制备方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108822120A true CN108822120A (zh) | 2018-11-16 |
Family
ID=64135938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810758019.0A Pending CN108822120A (zh) | 2018-07-11 | 2018-07-11 | Fl118氨基酸盐酸盐及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108822120A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111171041A (zh) * | 2018-11-12 | 2020-05-19 | 中国海洋大学 | 20位取代的喜树碱衍生物及其制备方法和应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4943579A (en) * | 1987-10-06 | 1990-07-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble prodrugs of camptothecin |
WO1996002546A1 (en) * | 1994-07-20 | 1996-02-01 | Research Triangle Institute | Water-soluble esters of camptothecin compounds |
WO1996009049A1 (en) * | 1994-09-22 | 1996-03-28 | Research Triangle Institute | Inhibition of plasmodia parasites by camptothecin compounds |
WO1997019085A1 (en) * | 1995-11-22 | 1997-05-29 | Research Triangle Institute | Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties |
US20020173468A1 (en) * | 1996-10-04 | 2002-11-21 | Hans-Georg Lerchen | Modified cytostatic agents |
US6492335B1 (en) * | 1996-09-30 | 2002-12-10 | Bayer Aktiengesellschaft | Glycoconjugates from modified camptothecin derivatives (20-O-linkage) |
-
2018
- 2018-07-11 CN CN201810758019.0A patent/CN108822120A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4943579A (en) * | 1987-10-06 | 1990-07-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble prodrugs of camptothecin |
WO1996002546A1 (en) * | 1994-07-20 | 1996-02-01 | Research Triangle Institute | Water-soluble esters of camptothecin compounds |
WO1996009049A1 (en) * | 1994-09-22 | 1996-03-28 | Research Triangle Institute | Inhibition of plasmodia parasites by camptothecin compounds |
WO1997019085A1 (en) * | 1995-11-22 | 1997-05-29 | Research Triangle Institute | Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties |
US6492335B1 (en) * | 1996-09-30 | 2002-12-10 | Bayer Aktiengesellschaft | Glycoconjugates from modified camptothecin derivatives (20-O-linkage) |
US20020173468A1 (en) * | 1996-10-04 | 2002-11-21 | Hans-Georg Lerchen | Modified cytostatic agents |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111171041A (zh) * | 2018-11-12 | 2020-05-19 | 中国海洋大学 | 20位取代的喜树碱衍生物及其制备方法和应用 |
WO2020098658A1 (zh) * | 2018-11-12 | 2020-05-22 | 中国海洋大学 | 20位取代的喜树碱衍生物及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10683304B2 (en) | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | |
CA2943220A1 (en) | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer | |
CN102295635B (zh) | 抗肿瘤药物四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用 | |
CN107629089A (zh) | 高活性的他克林‑铂(ii)配合物及其合成方法和应用 | |
CN106317018B (zh) | 一种肿瘤靶向性亲脂性阳离子-苯丁酸氮芥化合物及制备方法和在白蛋白纳米药物中的应用 | |
CN108822120A (zh) | Fl118氨基酸盐酸盐及其制备方法与应用 | |
CN110437156B (zh) | 丹皮酚二氢嘧啶酮类衍生物及其制备方法和应用 | |
CN110092789B (zh) | 一种吲哚并[2,3-b]咔唑衍生物及其应用 | |
CN105622704B (zh) | 抗肿瘤药物x-toa的制备方法及其应用 | |
CN106905193A (zh) | 芳酰基胍基奥司他韦羧酸衍生物及其制备方法和应用 | |
CN114437053B (zh) | 一种纳米探针与其在检测高尔基体中超氧阴离子的应用 | |
CN107266407B (zh) | 一种响应硝基还原酶杀灭肿瘤细胞的光敏感靶向抗肿瘤前药及其制备方法与应用 | |
CN104771392A (zh) | 一类组蛋白去乙酰化酶抑制剂及应用 | |
CN104817535A (zh) | 一种喹啉酮衍生物及其合成方法及应用 | |
CN105949139B (zh) | 一种仲丁基二苯基四嗪甲酰胺化合物及制备和应用 | |
CN104045598B (zh) | 一种含芳胺结构的硫脲类化合物及其制备方法和应用 | |
CN107320735A (zh) | 一种他莫昔芬组合物及其制剂 | |
CN111592498B (zh) | [2-(5′-氟尿嘧啶)乙酸-二乙基二硫代氨基甲酸]酐及在制备抗癌药物中的应用 | |
CN105481944B (zh) | 一种苯并咪唑衍生物二肽铜配合物及其制备方法和应用 | |
CN102786458B (zh) | 吡咯甲酰胺衍生物、其制备方法和用途 | |
CN102485735B (zh) | 6-果糖氨-4-芳胺基喹唑啉衍生物及其用途 | |
CN104672213A (zh) | 一种具有抗肿瘤活性的酰胺类化合物及其应用 | |
CN115260260B (zh) | 具有kga抑制活性的含硒核糖类化合物及其合成方法的应用 | |
CN104725431A (zh) | 喹啉酮衍生物的钴(ⅱ)配合物及其合成方法及应用 | |
CN103435586B (zh) | 含黄酮结构的多胺衍生物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181116 |
|
WD01 | Invention patent application deemed withdrawn after publication |